Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.
John E. Eaton,Jayant A. Talwalkar,Konstantinos N. Lazaridis,Gregory J. Gores,Keith D. Lindor +4 more
Reads0
Chats0
TLDR
Current understanding of this enigmatic disorder is reviewed, the recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease, and important topics for future studies are discussed.About:
This article is published in Gastroenterology.The article was published on 2013-09-01 and is currently open access. It has received 346 citations till now. The article focuses on the topics: Primary sclerosing cholangitis & Autoimmune pancreatitis.read more
Citations
More filters
Journal ArticleDOI
Burden of liver diseases in the world
TL;DR: The global prevalence of viral hepatitis remains high, while drug-induced liver injury continues to increase as a major cause of acute hepatitis.
Journal ArticleDOI
Molecular and cellular mechanisms of liver fibrosis and its regression.
TL;DR: This Review summarizes studies of the molecular mechanisms underlying the reversibility of liver fibrosis, including apoptosis and the inactivation of hepatic stellate cells, the crosstalk between the liver and the systems that orchestrate the recruitment of bone marrow-derived macrophages driving fibrosis resolution, and the interactions between various cell types that lead to the intracellular signalling that induces fibrosis or its regression.
Book ChapterDOI
Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer.
Tiangang Li,Udayan Apte +1 more
TL;DR: The mechanisms that regulate bile acid homeostasis and detoxification during cholestasis are covered, and the roles of bile acids in the initiation and regulation of hepatic inflammation, regeneration, and carcinogenesis are covered.
Journal ArticleDOI
Immunity, tolerance and autoimmunity in the liver: A comprehensive review.
TL;DR: The cellular mechanisms by which hepatic antigen-presenting cells and innate lymphocytes control the balance between immunity, tolerance and autoimmunity in the liver are reviewed.
Journal ArticleDOI
Recent advances in the development of farnesoid X receptor agonists
TL;DR: Together, these studies suggest that FXR agonists could potentially be used as therapeutic tools in patients suffering from nonalcoholic fatty and cholestatic liver diseases.
References
More filters
Journal ArticleDOI
IL-17 and Th17 Cells.
TL;DR: The investigation of the differentiation, effector function, and regulation of Th17 cells has opened up a new framework for understanding T cell differentiation and now appreciate the importance of Th 17 cells in clearing pathogens during host defense reactions and in inducing tissue inflammation in autoimmune disease.
Journal Article
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
Ulrich Beuers,Kirsten Muri Boberg,Roger W. Chapman,Olivier Chazouillères,Pietro Invernizzi,David Jones,Frank Lammert,Albert Parés,Michael Trauner +8 more
TL;DR: The clinical care for patients with cholestatic liver diseases has advanced considerably during recent decades thanks to growing insight into pathophysiological mechanisms and remarkable methodological and technical developments in diagnostic procedures as well as therapeutic and preventive approaches.
Journal ArticleDOI
Diagnosis and Management of Primary Sclerosing Cholangitis
Roger W. Chapman,Johan Fevery,Anthony N. Kalloo,David M. Nagorney,Kirsten Muri Boberg,Benjamin L. Shneider,Gregory J. Gores +6 more
TL;DR: Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic and preventative aspects of care that are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case.
Journal ArticleDOI
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)
Stuart Cairns,John H. Scholefield,Robert Steele,Malcolm G. Dunlop,Huw Thomas,Gareth Evans,Jayne Eaden,Matthew D. Rutter,Wendy P Atkin,Brian P. Saunders,Anneke Lucassen,Paul Jenkins,Peter D. Fairclough,Christopher R J Woodhouse,Ireland +14 more
TL;DR: Advice on the appropriateness, method and frequency of screening for people at moderate and high risk from colorectal cancer and for those with inflammatory bowel disease is provided.
Journal ArticleDOI
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn,Christopher Gasink,Long Long Gao,Marion Blank,Jewel Johanns,Cynthia Guzzo,Bruce E. Sands,Stephen B. Hanauer,Stephan R. Targan,Paul Rutgeerts,Subrata Ghosh,Willem J.S. de Villiers,Remo Panaccione,Gordon R. Greenberg,Stefan Schreiber,Simon Lichtiger,Brian G. Feagan +16 more
TL;DR: Patients with moderate-to-severe Crohn's disease that was resistant to TNF antagonists had an increased rate of response to induction with ustekinumab, as compared with placebo.
Related Papers (5)
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.
Kirsten Boonstra,Rinse K. Weersma,Karel J. van Erpecum,Erik A.J. Rauws,B W Marcel Spanier,Alexander C. Poen,Karin M.J. van Nieuwkerk,Joost P.H. Drenth,Ben J.M. Witteman,H.A.R.E. Tuynman,Anton H. Naber,Paul J. Kingma,Henk R. van Buuren,Bart van Hoek,Frank P. Vleggaar,Nan van Geloven,Ulrich Beuers,Cyriel Y. Ponsioen +17 more
High Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis
Keith D. Lindor,Kris V. Kowdley,Velimir A. Luketic,M. Edwyn Harrison,Timothy M. McCashland,Alex S. Befeler,Denise M. Harnois,Roberta A. Jorgensen,Jan Petz,Jill C. Keach,Jody Mooney,Carol Sargeant,Tamara Bernard,Debra King,Ellen Miceli,Jeff Schmoll,Tanya L. Hoskin,Prabin Thapa,Felicity Enders +18 more